Literature DB >> 21282576

Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3.

Quteba Ebrahem1, Jian Hua Qi, Masahiko Sugimoto, Mariya Ali, Jonathan E Sears, Alecia Cutler, Rama Khokha, Amit Vasanji, Bela Anand-Apte.   

Abstract

PURPOSE: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases (MMPs). The authors have previously determined a novel function of TIMP-3 to inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis. Here, the authors examined the in vivo angiogenic phenotype of ocular vessels in mice deficient in TIMP-3.
METHODS: VEGF-mediated corneal neovascularization and laser-induced choroidal neovascularization (CNV) were examined in TIMP-3-null mice. The effects of the absence of TIMP-3 on the phosphorylation status of the VEGF-receptor-2 (VEGFR-2) and the downstream signaling pathways were evaluated biochemically. In addition, the activation state of MMPs in the retina of TIMP-3-deficient mice was examined by in situ zymography.
RESULTS: The results of these studies determine an accentuation of pathologic VEGF-mediated angiogenesis in the cornea and laser-induced CNV in mice lacking TIMP-3. In the absence of the MMP inhibitor, pathophysiological changes were observed in the choroidal vasculature concomitantly with an increase in gelatinolytic activity. These results suggest that an imbalance of extracellular matrix homeostasis, together with a loss of an angiogenesis inhibitor, can prime vascular beds to be more responsive to an angiogenic stimulus.
CONCLUSIONS: In light of the recent studies suggesting that genetic variants near TIMP-3 influence susceptibility to age-related macular degeneration, these results imply that TIMP-3 may regulate the development of the choroidal vasculature and is a likely contributor to increased susceptibility to choroidal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282576      PMCID: PMC3175998          DOI: 10.1167/iovs.10-5899

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  54 in total

1.  Maturation of the fetal human choriocapillaris.

Authors:  Takayuki Baba; Rhonda Grebe; Takuya Hasegawa; Imran Bhutto; Carol Merges; D Scott McLeod; Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

2.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.

Authors:  Magali Saint-Geniez; Tomoki Kurihara; Eiichi Sekiyama; Angel E Maldonado; Patricia A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

3.  Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.

Authors:  C Schwesinger; C Yee; R M Rohan; A M Joussen; A Fernandez; T N Meyer; V Poulaki; J J Ma; T M Redmond; S Liu; A P Adamis; R J D'Amato
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.

Authors:  Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Complement factor H polymorphism and age-related macular degeneration.

Authors:  Albert O Edwards; Robert Ritter; Kenneth J Abel; Alisa Manning; Carolien Panhuysen; Lindsay A Farrer
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

6.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

Review 7.  Matrix-degrading proteases and angiogenesis during development and tumor formation.

Authors:  Z Werb; T H Vu; J L Rinkenberger; L M Coussens
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

8.  VEGF-induced choroidal damage in a murine model of retinal neovascularisation.

Authors:  L B G Tee; M A Penrose; J E O'Shea; C-M Lai; E P Rakoczy; S A Dunlop
Journal:  Br J Ophthalmol       Date:  2008-06       Impact factor: 4.638

9.  Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3.

Authors:  Andreas Janssen; Julia Hoellenriegel; Marton Fogarasi; Heinrich Schrewe; Mathias Seeliger; Ernst Tamm; Andreas Ohlmann; Christian Albrecht May; Bernhard H F Weber; Heidi Stöhr
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-11       Impact factor: 4.799

10.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

Authors:  A Amour; P M Slocombe; A Webster; M Butler; C G Knight; B J Smith; P E Stephens; C Shelley; M Hutton; V Knäuper; A J Docherty; G Murphy
Journal:  FEBS Lett       Date:  1998-09-11       Impact factor: 4.124

View more
  15 in total

1.  Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.

Authors:  Nina Jasmin Hewing; Gisela Weskamp; Joost Vermaat; Eric Farage; Krzysztof Glomski; Steven Swendeman; Robison Vernon Paul Chan; Michael F Chiang; Rama Khokha; Bela Anand-Apte; Carl Peter Blobel
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-30       Impact factor: 4.799

2.  Inhibition of choroidal neovascularization by systemic delivery of gold nanoparticles.

Authors:  Rupesh Singh; Julia C Batoki; Mariya Ali; Vera L Bonilha; Bela Anand-Apte
Journal:  Nanomedicine       Date:  2020-04-17       Impact factor: 5.307

3.  Innate Immunity in Age-Related Macular Degeneration.

Authors:  Yikui Zhang; Wai T Wong
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor.

Authors:  Mayur Choudhary; Stephen Safe; Goldis Malek
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-02-23       Impact factor: 5.187

5.  Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL.

Authors:  Marie Monet-Leprêtre; Iman Haddad; Céline Baron-Menguy; Maï Fouillot-Panchal; Meriem Riani; Valérie Domenga-Denier; Claire Dussaule; Emmanuel Cognat; Joelle Vinh; Anne Joutel
Journal:  Brain       Date:  2013-05-06       Impact factor: 13.501

6.  Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS.

Authors:  Yantenew G Gete; Luke W Koblan; Xiaojing Mao; Mason Trappio; Bhushan Mahadik; John P Fisher; David R Liu; Kan Cao
Journal:  Aging Cell       Date:  2021-06-04       Impact factor: 9.304

7.  A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice.

Authors:  Yung-Yi Chen; Nicola J Brown; Rita Jones; Claire E Lewis; Ahmed H Mujamammi; Munitta Muthana; Michael P Seed; Michael D Barker
Journal:  Angiogenesis       Date:  2013-10-16       Impact factor: 9.596

8.  Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Authors:  Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration.

Authors:  Renpan Zeng; Feng Wen; Xiongze Zhang; Yu Su
Journal:  Mol Vis       Date:  2013-03-21       Impact factor: 2.367

Review 10.  Can Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby's Fundus Dystrophy.

Authors:  Hanae C Y Gourier; N Victor Chong
Journal:  J Clin Med       Date:  2015-05-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.